Search

Displaying results 9121 - 9130 of 10000 in total
  1. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  2. Drug

    RH-1

    go.drugbank.com/drugs/DB04090
    Investigational

    RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.

  3. Drug

    Misonidazole

    go.drugbank.com/drugs/DB11716
    Investigational

    Misonidazole is under investigation in clinical trial NCT00038038 (Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole).

  4. Drug

    Funapide

    go.drugbank.com/drugs/DB11769
    Investigational

    Funapide has been used in trials studying the treatment of Pharmacokinetics, Postherpetic Neuralgia, and Osteoarthritis of the Knee.

  5. Drug

    Tretamine

    go.drugbank.com/drugs/DB14031
    Experimental

    Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.

  6. Drug

    Selicrelumab

    go.drugbank.com/drugs/DB14958
    Investigational

    Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).

  7. Drug

    OPC1

    go.drugbank.com/drugs/DB17944
    Experimental

    OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.[L47082]

  8. Drug

    NGN-101

    go.drugbank.com/drugs/DB18335
    Investigational

    NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene

  9. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.

  10. Drug

    Prosetin

    go.drugbank.com/drugs/DB18649
    Investigational

    Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]